Difficulty: Medium
Average Score: 90%
Testbank
A client with breast cancer is scheduled to undergo chemotherapy with aromatase inhibitors. Which rationale does the nurse give for the use of this group of drugs?
Correct answer
A
Rationale
A: They prevent prehormones from becoming estrogen, blocking the tumor's ability to use it.
Aromatase inhibitors work by inhibiting the aromatase enzyme, which is responsible for converting androgens into estrogens in postmenopausal women. This reduction in estrogen levels hinders the growth of estrogen-dependent tumors, such as certain types of breast cancer, by depriving them of the hormone they require for growth and proliferation.
B: They block progesterone-dependent tumors from growing. Aromatase inhibitors specifically target estrogen production rather than progesterone, making this option irrelevant for the treatment of estrogen receptor-positive breast cancer.
C: They attack to endogenous protein receptors to slow the growth of cancerous cells. This option misrepresents the mechanism of aromatase inhibitors, which do not directly bind to receptors but instead reduce estrogen synthesis, thus limiting its availability to cancer cells.
D: They stimulate the immune system to attack a protein common in many tumors. This option describes an immunotherapy approach, which is not the mechanism of aromatase inhibitors, as they do not directly engage the immune system but rather inhibit estrogen production.
Aromatase inhibitors work by inhibiting the aromatase enzyme, which is responsible for converting androgens into estrogens in postmenopausal women. This reduction in estrogen levels hinders the growth of estrogen-dependent tumors, such as certain types of breast cancer, by depriving them of the hormone they require for growth and proliferation.
B: They block progesterone-dependent tumors from growing. Aromatase inhibitors specifically target estrogen production rather than progesterone, making this option irrelevant for the treatment of estrogen receptor-positive breast cancer.
C: They attack to endogenous protein receptors to slow the growth of cancerous cells. This option misrepresents the mechanism of aromatase inhibitors, which do not directly bind to receptors but instead reduce estrogen synthesis, thus limiting its availability to cancer cells.
D: They stimulate the immune system to attack a protein common in many tumors. This option describes an immunotherapy approach, which is not the mechanism of aromatase inhibitors, as they do not directly engage the immune system but rather inhibit estrogen production.